Impact BioMedical Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IBO research report →
Companywww.impactbiomedinc.com
Impact BioMedical Inc. engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. It provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone.
- CEO
- Frank D. Heuszel
- IPO
- 2024
- Employees
- 2
- HQ
- Houston, TX, US
Price Chart
Valuation
- Market Cap
- $6.72M
- P/E
- -4.51
- P/S
- 172.44
- P/B
- 5.06
- EV/EBITDA
- -0.49
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -1743.59%
- Op Margin
- -11782.05%
- Net Margin
- -32969.23%
- ROE
- -2674.57%
- ROIC
- -24.85%
Growth & Income
- Revenue
- $32.00K · -98.63%
- Net Income
- $-11,838,000 · -477.02%
- EPS
- $-0.38 · -3700.00%
- Op Income
- $-4,270,000
- FCF YoY
- 66.46%
Performance & Tape
- 52W High
- $1.95
- 52W Low
- $0.36
- 50D MA
- $0.61
- 200D MA
- $0.56
- Beta
- 3.14
- Avg Volume
- 4.44M
Get TickerSpark's AI analysis on IBO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 25, 26 | Macko Todd D | sell | 1,600 |
| Mar 27, 26 | Macko Todd D | sell | 43,400 |
| Mar 23, 26 | Grady Jason | sell | 50,000 |
| May 22, 25 | DSS, INC. | sell | 115,600 |
| May 27, 25 | DSS, INC. | sell | 45,400 |
| May 22, 25 | DSS, INC. | sell | 115,600 |
| May 27, 25 | DSS, INC. | sell | 45,400 |
| Apr 4, 25 | DSS, INC. | sell | 890,800 |
| Apr 3, 25 | Chan Heng Fai Ambrose | sell | 351,555 |
| Apr 2, 25 | Chan Heng Fai Ambrose | sell | 300,000 |
Our IBO Coverage
We haven't published any research on IBO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IBO Report →